4. Baseline characteristics C.
| Study | Intensity of urogenital symptoms, mean (SD) (define symptoms and index/scale) | Menopausal symptom score, mean (SD) (define index/scale) | Quality of life, mean (SD) (define index/scale) | Sexuality, mean (SD) (define outcome measure) | Bone health, mean (SD) (define outcome measure) |
| Amsterdam 2009 | I1: NR | I1: NR | I1: 112.4 (19.5) (PGWBI) | I1: NR | I1: NR |
| C1: NR | C1: NR | C1: 115.2 (24.1) (PGWBI) | C1: NR | C1: NR | |
| Total: NR | Total: NR | Total: NR | Total: NR | Total: NR | |
| Bai 2007 | I1: NR | I1: NR | I1: NR | I1: NR | I1: NR |
| C1: NR | C1: NR | C1: NR | C1: NR | C1: NR | |
| Total: NR | Total: 24.7 (6.1) (KI) | Total: NR | Total: NR | Total: NR | |
| Bebenek 2010 | I1: NR | I1: 11.86 (4.71) (MRS) | I1: NR | I1: NR | I1: 0.97 (0.13) (BMD, lumbar) |
| I1: 0.77 (0.10) (BMD, fem. head) | |||||
| I2: NR | I2: 10.84 (5.35) (MRS) | I2: NR | I2: NR | I2: 0.96 (0.12) (BMD, lumbar) | |
| I2: 0.76 (0.10) (BMD, fem. head) | |||||
| C1: NR | C1: 9.88 (3.48) (MRS) | C1: NR | C1: NR | C1: 0.99 (0.13) (BMD, lumbar) | |
| C1: 0.75 (0.11) (BMD, fem. head) | |||||
| Total: NR | Total: NR | Total: NR | Total: NR | Totals: NR | |
| Carlisle 2008 | I1: NR | I1: NR | I1: NR | I1: NR | I1: 10.65 (2.78) (serum osteocalcin, ng/mL) |
| I1: 0.48 (0.25) (C‐terminal telopeptide, ng/mL) | |||||
| C1: NR | C1: NR | C1: NR | C1: NR | C1: 11.19 (4.16) (serum osteocalcin, ng/mL) | |
| C1: 0.56 (0.32) (C‐terminal telopeptide, ng/mL) | |||||
| Total: NR | Total: NR | Total: NR | Total: NR | Totals: NR | |
| Frei‐Kleiner 2005 | I1: NR | I1: 19.5 (7.9) (KI) | I1: NR | I1: NR | I1: NR |
| C1: NR | C1: 19.0 (7.2) (KI) | C1: NR | C1: NR | C1: NR | |
| Total: NR | Total: NR | Total: NR | Total: NR | Total: NR | |
| Geller 2009 | I1: 0.8 (1.0) | I1: 18.2 (5.4) | I1: NR | I1: NR | I1: NR |
| I2: 1.1 (1.0) | I2: 22.5 (8.1) | I2: NR | I2: NR | I2: NR | |
| I3: 0.7 (0.9) | I3: 19.2 (7.8) | I3: NR | I3: NR | I3: NR | |
| C1: 1.1 (0.9) | C1: 20.7 (6.6) | C1: NR | C1: NR | C1: NR | |
| Total: NR | Total: NR | Total: NR | Total: NR | Total: NR | |
| (Vaginal dryness, 3‐point scale) | |||||
| Jacobson 2001 | I1: NR | I1: NR | I1: NR | I1: NR | I1: NR |
| C1: NR | C1: NR | C1: NR | C1: NR | C1: NR | |
| Total: NR | Total: NR | Total: NR | Total: NR | Total: NR | |
| Kronenberg 2009 | I1: NR | I1: 18.5 (8.8) (GCS) | I1: NR | I1: NR | I1: NR |
| C1: NR | C1: 19.1 (9.6) (GCS) | C1: NR | C1: NR | C1: NR | |
| Total: NR | Total: 18.8 (9.2) (GCS) | Total: NR | Total: NR | Total: NR | |
| Lehmann‐Willenbrock 1988 | I1: NR | I1: 48.73 (8.72) (KI) | I1: NR | I1: NR | I1: NR |
| C1: NR | C1: 49.12 (7.76) (KI) | C1: NR | C1: NR | C1: NR | |
| C2: NR | C2: 46.44 (8.18) (KI) | C2: NR | C2: NR | C2: NR | |
| C3: NR | C3: 47.84 (8.52) (KI) | C3: NR | C3: NR | C3: NR | |
| Total: NR | Total: NR | Total: NR | Total: NR | Total: NR | |
| Nappi 2005 | I1: NR | I1: 7.5 (0.6) (GCS) | I1: NR | I1: NR | I1: NR |
| C1: NR | C1: 8.0 (0.9) (GCS) | C1: NR | C1: NR | C1: NR | |
| Total: NR | Total: NR | Total: NR | Total: NR | Total: NR | |
| Newton 2006 / Reed 2008 | I1: NR | I1: 2.2 (1.2) | I1: NR | I1: NR | I1: NR |
| I2: NR | I2: 2.2 (1.1) | I2: NR | I2: NR | I2: NR | |
| I3: NR | I3: 2.2 (1.2) | I3: NR | I3: NR | I3: NR | |
| I4: NR | I4: 2.1 (1.0) | I4: NR | I4: NR | I4: NR | |
| C1: NR | C1: 2.5 (1.2) | C1: NR | C1: NR | C1: NR | |
| Total: NR | Total: 2.3 (1.2) | Total: NR | Total: NR | Total: NR | |
| Oktem 2007 | I1: NR | I1: 25.1 (6.7) (mKI) | I1: NR | I1: NR | I1: NR |
| C1: NR | C1: 25.2 (6.8) (mKI) | C1: NR | C1: NR | C1: NR | |
| Total: NR | Total: NR | Total: NR | Total: NR | Total: NR | |
| Osmers 2005 | I1: NR | I1: 0.35 (0.12) (MRS) | I1: NR | I1: NR | I1: NR |
| C1: NR | C1: 0.35 (0.12) (MRS) | C1: NR | C1: NR | C1: NR | |
| Total: NR | Total: NR | Total: NR | Total: NR | Total: NR | |
| Pockaj 2006 | I1: NR | I1: NR | I1: NR | I1: NR | I1: NR |
| C1: NR | C1: NR | C1: NR | C1: NR | C1: NR | |
| Total: NR | Total: NR | Total: NR | Total: NR | Total: NR | |
| Stoll 1987 | I1: NR | I1: 34.4 (‐) (KI) | I1: NR | I1: 1.9 (‐) (NSC) | I1: NR |
| C1: NR | C1: 34.0 (‐) (KI) | C1: NR | C1: 1.5 (‐) (NSC) | C1: NR | |
| C2: NR | C2: 31.0 (‐) (KI) | C2: NR | C2: 1.6 (‐) (NSC) | C2: NR | |
| Total: NR | Total: NR | Total: NR | Total: NR | Total: NR | |
| Wuttke 2003/2006a/2006b | I1: NR | I1: 2.73 (0.52) (MRS) | I1: NR | I1: NR | I1: 0.25 (0.2) (CrossLaps, ng/mL) |
| C1: NR | C1: 2.83 (0.51) (MRS) | C1: NR | C1: NR | C1: 0.24 (0.12) (CrossLaps, ng/mL) | |
| C2: NR | C2: 3.23 (1.0) (MRS) | C2: NR | C2: NR | C2: 0.25 (1.6) (CrossLaps, ng/mL) | |
| Total: NR | Total: NR | Total: NR | Total: NR | Total: NR |
BMD: bone mineral density; C: control; GCS: Greene Climacteric Scale; I: intervention; KI: Kupperman Index; MDP: medroxyprogesterone; mKI: Modified Kupperman index; MRS: Menopause Rating Scale; NR: not recorded; NSC: number of sexual complaints; PGWBI: Psychological General Wellbeing Index; WMSS: = Wiklund Menopause Symptom Score.